Key Points
- COO Michael Benkowitz sold 22,500 shares on Dec. 1 at an average price of $479.91 (about $10.8M), and executed 11 weekly sales of 22,500 shares from Sept. 22–Dec. 1 — roughly 247,500 shares sold for about $110M in total.
- United Therapeutics trades near its 52‑week high with a $20.4B market cap, recently beat quarterly EPS estimates, and carries a consensus "Moderate Buy" from analysts with an average price target of $505.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the business's stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $481.93, for a total transaction of $1,927,720.00. Following the completion of the transaction, the chief executive officer owned 130 shares of the company's stock, valued at $62,650.90. This represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
United Therapeutics Stock Performance
NASDAQ:UTHR opened at $474.14 on Wednesday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $492.62. The stock has a market capitalization of $20.42 billion, a P/E ratio of 17.97, a P/E/G ratio of 4.96 and a beta of 0.77. The company's 50-day simple moving average is $449.76 and its 200-day simple moving average is $364.99.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same quarter in the previous year, the business posted $6.39 EPS. United Therapeutics's revenue was up 6.8% on a year-over-year basis. On average, research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on the company. HC Wainwright upped their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a "buy" rating in a research report on Thursday, October 30th. Royal Bank Of Canada upped their target price on United Therapeutics from $569.00 to $587.00 and gave the company an "outperform" rating in a research report on Thursday, October 30th. UBS Group raised their price target on United Therapeutics from $580.00 to $600.00 and gave the stock a "buy" rating in a report on Thursday, November 6th. Bank of America boosted their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 2nd. Finally, Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research report on Wednesday, September 10th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $505.00.
View Our Latest Analysis on United Therapeutics
Hedge Funds Weigh In On United Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC boosted its holdings in shares of United Therapeutics by 204.3% in the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company's stock valued at $1,492,000 after acquiring an additional 3,487 shares during the last quarter. AXQ Capital LP lifted its position in United Therapeutics by 495.4% during the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company's stock valued at $1,117,000 after purchasing an additional 3,235 shares during the period. XTX Topco Ltd purchased a new stake in United Therapeutics in the first quarter valued at $313,000. LPL Financial LLC grew its position in United Therapeutics by 77.3% during the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after purchasing an additional 11,007 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of United Therapeutics by 77.4% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company's stock valued at $1,792,000 after buying an additional 2,655 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
